Last reviewed · How we verify
Celestone
At a glance
| Generic name | Celestone |
|---|---|
| Also known as | Betamethasone Sodium Phosphate, Corticosteroid |
| Sponsor | Gaziler Physical Medicine and Rehabilitation Education and Research Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination (PHASE1)
- Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis (NA)
- Assessing Psoriasis Treatment Outcomes (NA)
- A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects (PHASE3)
- Comparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty (NA)
- Ropiclobet for Regional Anesthesia and Post-Operative Pain Control in Upper Extremity Surgery (PHASE2)
- Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS) (PHASE4)
- Betamethasone and Complications of Lower Third Molar Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Celestone CI brief — competitive landscape report
- Celestone updates RSS · CI watch RSS
- Gaziler Physical Medicine and Rehabilitation Education and Research Hospital portfolio CI